25th week of 2011 patent applcation highlights part 64 |
Patent application number | Title | Published |
20110152282 | HEDGEHOG PATHWAY MODULATORS - The invention provides a method, compounds and compositions for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or GIi gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula (I). | 2011-06-23 |
20110152283 | CRYSTALLINE PIMOBENDAN, PROCESS FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION AND USE - The invention relates to a pharmaceutical composition containing pimobendan as an active ingredient. The invention also relates to a crystalline form of pimobendan, as well as to a combination of said crystalline form with at least one other therapeutically active ingredient. Moreover, the invention relates to uses of said crystalline form, as well as to a pharmaceutical composition containing it. Finally, the invention relates to a process for preparing a crystalline form of pimobendan. | 2011-06-23 |
20110152284 | Sigma ligands for neuronal regeneration and functional recovery - The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptor, wherein the ligand is preferable AGY-94806, or salts or solvates thereof. These molecules can be delivered alone or in combination with agents which treat or prevent neurodegenerative diseases such as those caused by ischemic stroke, multiple sclerosis, amyotrophic lateral sclerosis, traumatic brain injury, Huntington's disease, or Parkinson's disease. In other methods, the sigma receptor ligands are administered after stroke to facilitate functional recovery. The administration of the sigma receptor ligands effects functional recovery. | 2011-06-23 |
20110152285 | PYRROLE ANTIFUNGAL AGENTS - The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof; wherein: R1, R2, R3, R4, R5, R6, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides. | 2011-06-23 |
20110152286 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS - The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety. | 2011-06-23 |
20110152287 | SUBSTITUTED BENZOTHIAZOLE AND BENZOXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 - The present invention is directed to substituted benzothiazole and benzoxazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by DPP-1. | 2011-06-23 |
20110152288 | METHODS OF TREATING VASOMOTOR SYMPTOMS - The present invention relates to methods for treating, preventing or controlling vasomotor symptoms such as hot flashes comprising administering specific norepinephrine/serotonin reuptake inhibitors. | 2011-06-23 |
20110152289 | DIMERIC DERIVATIVES OF ARTEMISININ AND APPLICATION IN ANTI-CANCER THERAPY - The present invention relates to dimeric derivatives of 10-trifluoromethylated artemisinin of formula (I) below: Formula (I) and the pharmaceutically acceptable salts thereof, and also to the preparation method thereof and to the uses thereof, especially in the treatment of cancer. | 2011-06-23 |
20110152290 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS - The present invention relates to compounds of the formula I, | 2011-06-23 |
20110152291 | NOVEL AROMATIC COMPOUNDS AND THEIR USE IN MEDICAL APPLICATIONS - Pharmaceutical compositions comprising at least one compound of the formulas (Ia) or (Ib) and a pharmaceutically acceptable carrier wherein the symbols have the following meaning —X- is e.g. and Y being e.g. or the pharmaceutically acceptable salts can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding. | 2011-06-23 |
20110152292 | SALTS COMPRISING A PYRIMIDINECARBOXYLIC ACID DERIVATIVE FOR COSMETIC USE - The invention relates to novel compounds which comprise, as cationic or as anionic component, a pyrimidinecarboxylic acid derivative, in particular a derivative of ectoin or hydroxyectoin, to a process for the preparation thereof, and to the use thereof as ionic liquid or to the use thereof in pharmaceutical, cosmetic and dermatological formulations. | 2011-06-23 |
20110152293 | ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF - Novel vinylazacycloalkane compounds of Formula (I) are disclosed. The compounds are ligands of various nAChRs. The compounds and their pharmaceutically acceptable salts can be used to prepare pharmaceutical compositions and/or medicaments intended to prevent or treat disorders associated with dysfunction of nAChRs, especially within the central nervous system or the gastrointestinal system. Examples of types of disorders that can be treated include neurodegenerative disorders, including central nervous system disorders such as Alzheimer's disease, cognitive disorders, motor disorders such as Parkinson's disease, drug addiction, behavioral disorders and inflammatory disorders within the gastrointestinal system. The compounds can also serve as analgesics in the treatment of acute, chronic or recurrent pain. | 2011-06-23 |
20110152294 | USE OF OSMOLYTES OBTAINED FROM EXTREMOPHILIC BACTERIA FOR THE PRODUCTION OF INHALABLE MEDICAMENTS FOR THE PROPHYLAXIS AND TREATMENT OF PULMONARY AND CARDIOVASCULAR DISEASES AND AN INHALATION DEVICE COMPRISING OSMOLYTE AS ACTIVE AGENT COMPONENT - The invention relates to the use of osmolytes, for example, ectoine, hydroxyectoine, firoin, firoin-A, diglycerol phosphate, cyclic diphosphoglycerate, 1,3-dimannosyl-di-myo-inositol-phosphate (DMIP) and/or diinositol phosphate and their equally effective derivatives and/or pharmacologically acceptable salts thereof, for the combating of pulmonary diseases caused by the effect of airborne particles and/or causally related cardiovascular diseases. | 2011-06-23 |
20110152295 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE - Heteroaromatic compounds of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis. | 2011-06-23 |
20110152296 | HETEROCYCLIC COMPOUNDS AND THEIR USES - Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer. | 2011-06-23 |
20110152297 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS - The invention concerns quinazoline derivatives of the Formula I, or pharmaceutically acceptable salts thereof: | 2011-06-23 |
20110152298 | IMIDAZO [2,1-B] QUINAZOLIN-2-ONE DERIVATIVES AND THEIR USE AS PLATELET ANTI-AGGREGATIVE AGENTS - This invention relates to the discovery of substituted analogues of the selective platelet lowering agent anagrelide with reduced potential for cardiovascular side-effects which should lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to certain imidazoquinazoline derivatives which have the general formula shown below where the substituents have the meanings defined in claim (I) and which have utility as platelet lowering agents in humans. The compounds of the present invention function by inhibiting megakaryocytopoeisis and hence the formation of blood platelets. | 2011-06-23 |
20110152299 | SUBSTITUTED BENZAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME - Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention | 2011-06-23 |
20110152300 | 2-ALDOXIMINO-5-FLUOROPYRIMIDINE DERIVATIVES - This present disclosure is related to the field of 2-aldoximino-5-fluoropyrimidines and their derivatives and to the use of these compounds as fungicides. | 2011-06-23 |
20110152301 | Compounds that Inhibit HIV Particle Formation - The present invention describes novel methods of identifying compounds which inhibit HIV particle formation and Rev-dependent HIV production. The present invention also provides methods and compounds for inhibiting HIV particle formation and or treating patients infected with HIV. | 2011-06-23 |
20110152302 | Novel dicyclanil-based shelf stable aqueous suspension and non-aqueous solution pour-on and spray-on formulations useful for the prevention and treatment of insect infestation in animals - This invention relates to topically active compositions, including pour-on and spray-on formulations, comprising insect growth regulator (IGR) insecticides prepared as aqueous suspension formulations, or as non-aqueous solution formulations, and to the methods of making these formulations, and to methods of using these formulations for the treatment and/or prevention of insect infestation in animals. | 2011-06-23 |
20110152303 | Chemical Compounds - Novel diarylpyrimidine derivatives and pharmaceutically acceptable salts, solvates or hydrates thereof, designed to inhibit HIV reverse transcriptase, are provided, and a pharmaceutical composition containing the same, especially an anti-HIV agent. More specifically, novel diarylpyrimidine derivatives that are derivatives of the HIV reverse transcriptase inhibitor TMC278 of formula (1 | 2011-06-23 |
20110152304 | SPIROAZAINDOLES - The present invention relates to spiroazaindole compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions. | 2011-06-23 |
20110152305 | FILMS AND PARTICLES - Described herein are compounds and processes that can be used to prepare polymer-based films, particles, gels and related compositions, and processes for delivery of agents, and other uses. | 2011-06-23 |
20110152306 | AZA-BRIDGED RING-FUSED INDOLES AND INDOLINES - The present application relates to indole and indoline derivatives of formula (I) | 2011-06-23 |
20110152307 | OPHTHALMIC COMPOSITION COMPRISING ASCOMYCIN - This invention relates to topical ophthalmic compositions comprising an ascomycin e.g. for the treatment of inflammatory diseases such as blepharitis. | 2011-06-23 |
20110152308 | AZA-RING FUSED INDOLE AND INDOLINE DERIVATIVES - The present application relates to indole and indoline derivatives of formula (I) | 2011-06-23 |
20110152309 | PHARMACEUTICAL, FOOD OR BEVERAGE HAVING INHIBITORY ACTIVITY ON SEROTONIN TRANSPORTER - There is provided a pharmaceutical agent, food, or beverage for treating or preventing a disease or condition that can be ameliorated by inhibiting serotonin reuptake, comprising a clinically-effective amount of (1S,3S)-1-methyl-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid. | 2011-06-23 |
20110152310 | TRICYCLIC TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY - The present invention relates to substituted tricyclic triazole compounds and compositions comprising substituted tricyclic triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a compound of the invention, or a composition comprising such a compound. | 2011-06-23 |
20110152311 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT - The present invention relates to novel crystalline forms of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) thereof. The present invention relates to compositions comprising a crystalline form of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil). Processes for the preparation of the crystalline forms and methods of treating bacterial infections by administering the crystalline forms alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil) are also described. | 2011-06-23 |
20110152312 | ANTIPARISITIC DIHYDROAZOLE COMPOUNDS AND COMPOSITIONS COMPRISING SAME - The present invention relates to novel dihydroazole of formula (I) and salts thereof: | 2011-06-23 |
20110152313 | SYNTHESIS OF AGELADINE A AND ANALOGS THEREOF - The invention describes a one pot process for synthesizing a compound of structure (I), or a tautomer thereof. A compound of structure (II), or a tautomer thereof, and an aldehyde of structure R | 2011-06-23 |
20110152314 | USE OF TENATOPRAZOLE FOR THE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE - The invention relates to a novel therapeutic application of tenatoprazole. Tenatoprazole and the salts thereof can be used in the production of a medicament for the treatment of atypical and esophageal symptoms of gastroesophageal reflux, gastrorrhagia and dyspepsia. | 2011-06-23 |
20110152315 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES - There is provided novel compounds capable of modulating the G-protein-coupled receptor GPR40, compositions comprising the compounds, and methods for their use for controlling insulin levels in vivo and for the treatment of conditions such as type I1 diabetes, hypertension, ketoacidosis, obesity, glucose intolerance, and hypercholesterolemia and related disorders associated with abnormally high or low plasma lipoprotein, triglyceride or glucose levels. | 2011-06-23 |
20110152316 | 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS - The present invention relates to 3,4-substituted piperidinyl-based renin inhibitor compounds bearing at 4-position Isoqumolone and having the Formula (I): The invention further relates to pharmaceutical compositions containing said compounds, as well as their use in treating cardiovascular events and renal insufficiency. | 2011-06-23 |
20110152317 | PREVENNTING THE OCCURRENCE OF OBESITY - Administration of autophagy inhibitor (e.g. 400 mg chloroquine daily) prevents occurrence of obesity and insulin resistance in human subject on prolonged high-fat diet. | 2011-06-23 |
20110152318 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME - This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, heart disease and so on. | 2011-06-23 |
20110152319 | METHOD TO PREDICT RESPONSE TO PHARMACOLOGICAL CHAPERONE TREATMENT OF DISEASES - The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining α-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of α-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease. | 2011-06-23 |
20110152320 | PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION - The subject of the invention is compounds of formula (I): | 2011-06-23 |
20110152321 | BICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 - The present invention is directed to novel bicyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by DPP-1. | 2011-06-23 |
20110152322 | Aminopropenoates as Fungicides - The present invention relates to aminopropenoate derivatives, the process of their preparation, intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants and in material protection, using these compounds or compositions. | 2011-06-23 |
20110152323 | Histone deacetylase inhibitors and uses thereof - The present invention discloses a group of histone deacetylase inhibitors and use thereof. The histone deacetylase inhibitors are useful in the treatment of malignant tumors and the diseases associated with differentiation and proliferation. The histone deacetylase inhibitors are the compounds represented by the following formula or salts thereof: | 2011-06-23 |
20110152324 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - A compound of formula: | 2011-06-23 |
20110152325 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS IV - The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity. | 2011-06-23 |
20110152326 | SUBSTITUTED ARYLOXOETHYL CYCLOPROPANECARBOXAMIDE COMPOUNDS AS VR1 RECEPTOR ANTAGONISTS - This invention provides a compound of the formula (I): (I) These compounds are useful for the treatment of disease conditions caused by overactivation of the VR1 receptor, such as pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound. | 2011-06-23 |
20110152327 | Pre-Mixed, Ready-To-Use Pharmaceutical Compositions - Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions. | 2011-06-23 |
20110152328 | Combination Therapy For Glaucoma - Disclosed herein is method of treating glaucoma or ocular hypertension comprising administering a prostaglandin agonist and a second therapeutically active agent to a mammal in need thereof, wherein said second therapeutically active agent is selected from: β-Blockers, Adrenergic Agonists, non-selective adrenergic agonists, α2-selective adrenergic agonists, Carbonic Anhydrase Inhibitors, Cholinergic Agonists, direct acting cholinergic agonists, chlolinesterase inhibitors, Glutamate Antagonists, Ca | 2011-06-23 |
20110152329 | Use of Epothilone Derivatives for the Treatment of Hyperparathyroidism - The present invention relates to a method of treating a warm-blooded animal, especially a human, having hyperparathyroidism comprising administering to said animal a therapeutically effective amount of an epothilone derivative of formula I | 2011-06-23 |
20110152330 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION - This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases. The invention also relates to intermediates useful in preparation of indane acetic derivatives and to methods of preparation. | 2011-06-23 |
20110152331 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION - This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases. The invention also relates to intermediates useful in preparation of indane acetic derivatives and to methods of preparation. | 2011-06-23 |
20110152332 | Pesticidal Heterocyclic Compounds - The present invention relates to novel pesticidal azolidine derivatives as well as to oxazolidinone derivatives and their use as pesticides for combating animal parasites which occur in the agrochemical field and in the field of veterinary medicine, respectively. | 2011-06-23 |
20110152333 | 3-CYANOPYRROLIDINYL-PHENYL-OXAZOLIDINONES AS ANTIBACTERIAL AGENTS - The invention provides new oxazolidinone compounds of formula (I) wherein R | 2011-06-23 |
20110152334 | MGLU2 AGONISTS - The present invention provides novel mGlu2 agonists useful in the treatment of bipolar disorder, schizophrenia, depression, and generalized anxiety disorder. | 2011-06-23 |
20110152335 | ALLANTOIN-CONTAINING SKIN CREAM - An allantoin-containing skin cream composition can comprise allantoin and at least one anionic or nonionic emulsifier that is substantially hydrophilic and is soluble in water. The pH of the composition is in a range of from about 3.0 to about 6.0; preferably, the pH of the composition is from about 5.0 to about 6.0. The composition can further comprise an acidic anionic polymer. A preferred acidic anionic polymer is a carboxypolymethylene polymer. The composition can further comprise a carbohydrate polymer such as galactoarabinan, polygalactose or polyarabinose. The composition can additionally comprise other ingredients such as herbal extracts, an antioxidant component, an emollient component, a chelator, a solvent component, or a preservative component. The composition is useful as a skin protectant. | 2011-06-23 |
20110152336 | COMBINATION THERAPY WITH PARP INHIBITORS - The present invention describes benzimidazole derivatives of Formula (I) which constitute potent PARP inhibitors in combination with radiotherapy or in combination with other chemotherapeutic agents. | 2011-06-23 |
20110152337 | 2,4,5-TRISUBSTITUTED IMIDAZOLES AND THEIR USE AS ANTI-MICROBIAL AGENTS - The present invention provides therapeutically effective 2,4,5-trisubstituted imidazole compounds, methods of preparing the same, and compositions comprising the compounds alone or in combination with other agents. The present invention further provides for the use of the compounds as anti-microbial agents. The anti-microbial properties of the compounds include anti-bacterial and/or anti-fungal activity. | 2011-06-23 |
20110152338 | CYCLOALKANE[B]INDOLE ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS - Described herein are compounds that are antagonists of PGD | 2011-06-23 |
20110152339 | FLUORESCENT REGULATORS OF RASSF1A EXPRESSION AND HUMAN CANCER CELL PROLIFERATION - The invention provides methods for the treatment of cancer in a subject comprising administering a dansyl-carbazole compound. | 2011-06-23 |
20110152340 | Methods for Identifying Subjects With an Increased Likelihood of Responding to DPP-IV Inhibitors - The invention provides novel in vitro diagnostic methods for identifying subjects or patients who may have an increased likelihood of responding to DPP-IV inhibitor therapy. The invention also provides novel polynucleotides associated with increased responsiveness of a patient to DPP-IV inhibition. Polynucleotide fragments which comprise at least one polymorphic locus, are also provided. Allele-specific primers and probes which hybridize to these polymorphic regions, and/or which comprise at least one polymorphic locus are also provided. The polynucleotides, primers, and probes of the invention are useful in phenotype correlations, medicine, and genetic analysis. | 2011-06-23 |
20110152341 | CLEAVAGE OF B-AMYLOID PRECURSOR PROTEIN - Methods and means for the identification of meprin-α and meprin-β as novel β-secretases and antagonists thereof for use in the treatment of amyloidosis. | 2011-06-23 |
20110152342 | STABILIZED PHARMACEUTICAL COMPOSITION - A pharmaceutical composition is provided which can easily be prepared and which can prevent decomposition of an aminoacetylpyrrolidine carbonitrile derivative, as an effective component, which derivative is in general instable in a pharmaceutical composition. | 2011-06-23 |
20110152343 | PROTEASE INHIBITORS AND BROAD-SPECTRUM ANTIVIRAL - Caspace inhibition provides inhibition of viral infection across a wide collection of caspaces and viruses. Caspace inhibition, the prevention of the formation of active caspaces, can be achieved either through gene therapy, protein binding an inhibition, or through small molecule administration. Examples for small molecule inhibition allow the formation of a pharmacaphore to identify more and more active small molecules. | 2011-06-23 |
20110152344 | Inhibition of filovirus entry into cells and uses thereof - The present invention discloses method to treat infections caused by filovirus. Such a method comprises blocking the PI3 kinase pathway or the calcium-associated pathway at the gene or protein level. Also disclosed herein are the compounds useful in the treatment of filoviral infection. | 2011-06-23 |
20110152345 | EBI3, DLX5, NPTX1 AND CDKN3 FOR TARGET GENES OF LUNG CANCER THERAPY AND DIAGNOSIS - The present invention relates to methods for treating or preventing lung cancer by administering a double-stranded molecule against one or more of EBI3, DLX5, NPTX1, CDKN3 or EF-I delta genes or compositions, vectors or cells containing such a double-stranded molecule. The present invention also features methods for diagnosing lung cancer, especially NSCLC or SCLC, using one or more over-expressed genes selected from among EBI3, DLX5, NPTX1, CDKN3 and/or EF-I delta. Also disclosed are methods of identifying compounds for treating and preventing lung cancer, using as an index their effect on the over-expression of one or more of EBI3, DLX5, CDKN3 and/or EF-I delta in the lung cancer, the cell proliferation function of one or more of EBI3, DLX5, NPTX1, CDKN3 and/or EF-I delta or the interaction between CDKN3 and VRS, EF-I beta, EF-I gamma and/or EF-I delta. | 2011-06-23 |
20110152346 | Use of Oligonucleotides with Modified Bases in Hybridization of Nucleic Acids - The invention is concerned with the use of oligonucleotide analogs that contain specifically modified DNA bases to be used in hybridization of nucleic acids, polymerase chain reaction (PCR) and siRNA-mediated gene silencing (RNAi). | 2011-06-23 |
20110152347 | Methods and compositions for controlling efficacy of RNA silencing - Based at least in part on an understanding of the mechanisms by which small RNAs (e.g., naturally-occurring miRNAs) mediate RNA silencing in plants, rules have been established for determining, for example, the degree of complementarity required between an RNAi-mediating agent and its target, i.e., whether mismatches are tolerated, the number of mismatches tolerated, the effect of the position of the mismatches, etc. Such rules are useful, in particular, in the design of improved RNAi-mediating agents which allow for more exact control of the efficacy of RNA silencing. | 2011-06-23 |
20110152348 | METHODS FOR TREATING ANDROGEN RECEPTOR DEPENDENT DISORDERS INCLUDING CANCERS - The invention provides the combination use of antisense oligomers targeting androgen receptor mRNA and androgen receptor binding inhibitors that reduce androgen receptor activity for the treatment of androgen receptor related medical disorders, such as cancers, particularly prostate cancers and breast cancers. | 2011-06-23 |
20110152349 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF IL-18 GENES - The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a IL-18 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a IL-18 gene using said pharmaceutical composition; and methods for inhibiting the expression of IL-18 in a cell. | 2011-06-23 |
20110152350 | Compositions and Methods for Inhibiting Expression of XBP-1 Gene - The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting X-Box Protein 1 (XBP-1), and methods of using the dsRNA to inhibit expression of XBP-1. | 2011-06-23 |
20110152351 | MODULATION OF SMRT EXPRESSION - Disclosed herein are compounds and methods for decreasing SMRT and treating metabolic and/or cardiovascular diseases in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to SMRT include obesity, diabetes, dyslipidemia, and hypothyroidism. | 2011-06-23 |
20110152352 | SMAD PROTEINS CONTROL DROSHA-MEDIATED MIRNA MATURATION - The invention, in some aspects, relates to compositions and methods useful for modulating expression of miRNAs that are regulated by the TGF-β/BMP signaling pathway. In some aspects, the invention relates, to oligonucleotides comprising a CAGRN-motif that modulate expression of miRNAs that are regulated by TGF-β/BMP signaling pathway. The invention, in some aspects, relates to composition and methods useful for inhibiting microRNA processing. In some aspects, the invention relates to composition and methods for treating TGF-Beta/BMP mediated disorders. | 2011-06-23 |
20110152353 | DOUBLE-STRANDED POLYNUCLEOTIDE - It is intended to provide a double-stranded polynucleotide that is resistant to RNase and has RNA interference effect, etc. The present invention provides a double-stranded polynucleotide comprising sense and antisense strands comprising polynucleotides comprising a nucleotide unit of DNAs and 2′-O-methyl RNAs alternately combined. | 2011-06-23 |
20110152354 | Bispecific Oligonucleotide for the Treatment of CNS Malignancies - CNS malignancy is treated in a subject suffering from a CNS malignancy by administering to the subject an antisense oligonucleotide having a sequence of bases that is complementary to portions of both the gene encoding IGFBP-2 and the gene encoding IGFBP-5, and which is of sufficient length to act as an inhibitor of the effective amount of IGFBP-2 and IGFBP-5, in an amount effective to reduce effective levels of IGFBP-2 and IGFBP-5 in cells of the CNS malignancy. | 2011-06-23 |
20110152355 | METHOD FOR PREDICTING AND DETECTING TUMOR METASTASIS - The invention provides a method of determining the prognosis of cancer in a subject. The method comprises (a) obtaining a sample from the subject, (b) analyzing the sample for the expression level of a carboxypeptidase E (CPE) splice variant, and (c) correlating the expression level in the sample with the prognosis of cancer in the subject. The invention further provides a method of diagnosing cancer, methods of treatment, kits for detecting mRNA expression of a CPE-ΔN, and inhibitors of CPE-ΔN and compositions thereof. | 2011-06-23 |
20110152356 | NOVEL RNAi THERAPEUTIC FOR TREATMENT OF HEPATITIS C INFECTION - Small interfering RNAs (siRNAs) or small hairpin RNA (shRNAs) and compositions comprising same are provided that specifically target human cyclophilin A (CyPA) to effectively inhibit Hepatitis C(HCV) infection in a cell. Such siRNA and shRNAs may have a length of from about 19 to about 29 contiguous nucleotides corresponding to a specific region of human cyclophilin A (CyPA) cDNA of from about nucleotide 155 to about nucleotide 183 having particular potency against CyPA and HCV. Such siRNA and shRNAs may be formulated as naked compositions or as pharmaceutical compositions. DNA polynucleotides, plasmids, and viral or non-viral vectors are also provided that encode siRNA or shRNA molecules, which may be delivered directly to cells or in combination with known delivery agents, such as lipids, polymers, encapsulated lipid particles, such as liposomes. Methods for treating, managing inhibiting, preventing, etc., HCV infection using such siRNA and shRNAs and compositions comprising same are also provided. | 2011-06-23 |
20110152357 | Micro-RNA-Based Compositions and Methods for the Diagnosis, Prognosis and Treatment of Multiple Myeloma - Methods for assessing a pathological condition in a subject includes measuring an expression profile of one or more markers where a difference is indicative of multiple myeloma (MM) or a predisposition to MM. The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of MM. The invention also provides methods of identifying anti-MM cancer agents. | 2011-06-23 |
20110152358 | Compositions and Methods for Diagnosis and Treatment of Pancreatic Ductal Cancer - The present invention includes compositions and methods for diagnosing and treating pancreatic cancer. These compositions and methods are based on the finding that 14-3-3σ protein is secreted from pancreatic cancer cells and is therefore a specific biomarker protein. | 2011-06-23 |
20110152359 | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising threreof - Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided. | 2011-06-23 |
20110152360 | LIQUID PHARMACEUTICAL FORMULATIONS OF DOCETAXEL - There is provided a liquid pharmaceutical formulation for parenteral administration comprising: docetaxel or a pharmaceutically acceptable salt thereof; one or more glycols; and a pharmaceutically acceptable nonaqueous solvent system; wherein the formulation has a pH meter reading in the range of from 2.5 to 7. | 2011-06-23 |
20110152361 | NOVEL EPIGALLOCATECHIN GALLATE TETRAMER AND VASCULAR ENDOTHELIAL FUNCTION IMPROVING AGENT CONTAINING THE SAME - Providing a compound capable of continuously taking and having a vascular endothelial function improving effect by enhancing NO function from the vascular endothelial cells. | 2011-06-23 |
20110152362 | METHODS OF TREATING EPILEPTOGENESIS AND EPILEPSY - This invention is directed to methods for preventing, treating, reversing, inhibiting or arresting epilepsy and epileptogenesis in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II), or a pharmaceutically acceptable salt or ester thereof: | 2011-06-23 |
20110152363 | ORGANICALLY CHELATED MINERAL COMPOSITIONS AND METHODS THEREOF - Embodiments of the invention relate to a method of making a mineral product. The method includes contacting a carboxylic acid and an inorganic mineral compound sufficient to form a solution, reacting the solution over a period of time sufficient to provide a mineral chelated compound, transferring the mineral chelated compound to one or more molds prior to the compound substantially solidifying and reducing the size of the mineral chelated compound sufficient to provide a rapidly soluble mineral chelated product. | 2011-06-23 |
20110152364 | COMPOSITIONS FOR REPELLING FLUID AND USES THEREOF - Provided are compositions for repelling fluids comprising a volatile liquid carrier, a powder-feel agent and less than 5 weight % of an ester selected from the group consisting of formula I, formula II, formula III, and combinations of two or more thereof: | 2011-06-23 |
20110152365 | DISINFECTANT FORMULATIONS THAT REMAIN LIQUID AT LOW TEMPERATURE - In the present invention, there is provided a disinfectant composition comprising
| 2011-06-23 |
20110152366 | N-alkylcarbonyl-amino acid ester compounds and their use for skin irritation, itch, and pain - The present invention generally relates to refreshing, soothing, and cooling compounds that affect sensory processes. More particularly, the present invention pertains to certain N-alkylcarbonyl- | 2011-06-23 |
20110152367 | PROCESS FOR THE PREPARATION OF FESOTERODINE WITH LOW IMPURITIES CONTENT - Disclosed is a process for the preparation of (R)-2-(3-diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)-phenol isobutyrate (Fesoterodine) or a pharmaceutically acceptable salt thereof having a low content of impurities such as tolterodine and tolterodine isobutyrate. | 2011-06-23 |
20110152368 | PERHYDROLASE PROVIDING IMPROVED PERACID STABILITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a | 2011-06-23 |
20110152369 | PERHYDROLASE PROVIDING IMPROVED PERACID STABILITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a | 2011-06-23 |
20110152370 | PERHYDROLASE PROVIDING IMPROVED PERACID STABILITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a | 2011-06-23 |
20110152371 | ANTIOXIDANT EXTRACT FROM FRUIT SKINS - The application generally relates to methods of inhibition of oxidation of polyunsaturated fatty acid—(PUFA) and/or lipid-containing foods and nutraceutical products. The application provides natural and consumer friendly method for preventing the oxidation or rancidity development of PUFA and/or lipids by incorporation of apple skin extracts as natural antioxidant in emulsions, bulk oil or other form of food and nutraceutical products. | 2011-06-23 |
20110152372 | ANHYDROUS PETROLEUM JELLY/ELASTOMER-FREE DEPIGMENTING COMPOSITIONS COMPRISING A SOLUBILIZED PHENOLIC COMPOUND AND A RETINOID - Novel dermatological depigmentation compositions, especially for topical application, contain as pharmaceutical active agents a dissolved phenolic compound and a retinoid, formulated as anhydrous compositions free of petroleum jelly and free of elastomer. | 2011-06-23 |
20110152373 | HAIR GROWTH PROMOTING AGENT CONTAINING 15,15-DIFLUOROPROSTAGLANDIN F2ALPHA DERIVATIVE AS ACTIVE INGREDIENT - The present invention provides a new pharmaceutical application of a 15,15-difluoroprostaglandin F | 2011-06-23 |
20110152374 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease - The invention relates to substituted phenoxyacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation. | 2011-06-23 |
20110152375 | METHOD OF REDUCING THE METHANE GAS LEVEL AND OF INCREASING THE TOTAL GAS YIELD IN ANIMAL FEED - The present invention relates to the use of at least one porous metal-organic framework material (MOF) comprising at least one first and, if appropriate, one second organic compound, where at least the first organic compound binds coordinatively to at least one metal ion in an at least partly bidentate manner, where the at least one metal ion is Mg(II) and where the first organic compound is derived from formic acid and the second organic compound from acetic acid, for reducing the methane level in the total gas produced, and to the use for increasing the total gas formation during feed digestion in ruminants as well as a method for reducing the methane level in the total gas produced and a method for increasing the total gas formation during feed digestion in ruminants. | 2011-06-23 |
20110152376 | 7-[3,5-DIHYDROXY-2- (3-HYDROXY-5-PHENYL-PENT-1-ENYL)- CYCLOPENTYL]-N-ETHYL-HEPT-5-ENAMIDE (BIMATOPROST) IN CRYSTALLINE FORM II, METHODS FOR PREPARATION, AND METHODS FOR USE THEREOF - The present invention provides a new crystalline form of bimatoprost, designated as crystalline form II. This new crystalline form is the most stable form known to date of bimatoprost. Moreover, it has been found that bimatoprost crystalline form II is readily prepared from crystalline form I. | 2011-06-23 |
20110152377 | EXTERNAL PREPARATION COMPRISING FATTY ACID SALT OR BENZOIC ACID SALT OF BASIC PHARMACOLOGICALLY ACTIVE COMPONENT, AND METHOD FOR PRODUCTION THEREOF - It has been demanded to develop a formulation for a novel external preparation having excellent transdermal absorption of a basic pharmacologically active component contained therein. It is found that the lipid solubility (logP values) of a basic pharmacologically active component and an organic acid (particularly a fatty acid) contribute significantly to the transdermal absorption of the basic pharmacologically active component in the selection of proper combinations of the basic pharmacologically active component and the organic acid. Namely, it is found that superior transdermal absorption of a basic pharmacologically active component having a lipid solubility level of 0.5 to 5 can be achieved by forming a salt of the component with a fatty acid having a lipid solubility level of −1 to 4. Thus, it becomes possible to provide a novel external preparation having excellent transdermal absorption properties. | 2011-06-23 |
20110152378 | DISINFECTANT FORMULATIONS SUITABLE FOR USE AT LOW TEMPERATURE - There is provided a disinfectant composition comprising
| 2011-06-23 |
20110152379 | COMPOSITION FOR CONTROL OF AGING AND/OR EXTENSION OF LIFE, CONTAINING DAPSONE AS ACTIVE INGREDIENT - The present invention relates to a composition for controlling aging and/or extending lifespan. More specifically, the present invention relates to a composition containing dapsone as an effective component for controlling aging and/or extending lifespan, in which when applying the composition according to the present invention to an object, the effect of controlling aging or extending lifespan is excellent. Specifically, the treatment of dapsone (DDS) increases the lifespan of | 2011-06-23 |
20110152380 | Paediatric Compositions For Treating Multiple Sclerosis - The present invention relates to pharmaceutical compositions comprising a 2-amino-2-[2-(4-C | 2011-06-23 |
20110152381 | 3-KETO-N-PROPARGYL-1-AMINOINDAN - The subject invention provides a pharmaceutical composition containing N-propargyl-1(R)-aminoindan or a pharmaceutically acceptable salt thereof, and a compound of 3-keto-N-propargyl-1-aminoindan or a salt thereof. | 2011-06-23 |